Increased level of neuron-specific enolase is associated with small-cell lung cancer and non-small cell lung cancer patients

There is complementarity in the combined detection of the level of TPS, NSE, CEA and beta(2)-MG. Their levels have close correlation with lung cancer, histological grades and lymphoid nodule metastasis.

NSE gene expression promotes the cell proliferation and inhibits the cell apoptosis in lung cancer cells with neuroendocrine differentiation.

NSE is an ideal tumor marker for the diagnosis and assessment prognosis of small cell lung cancer

SCC, CEA, Cyfra 21-1 and NSE are valuable in the early diagnosis of lung cancer among suspicious nodules in the lung, especially when they were assayed together for one patient.

The high serum levels of NSE in small cell lung cancer differed significantly from all other cancers including non-small cell lung cancer.

Data show that the prognostic values of CA125, CA19.9, neuron-speci fi c enolase (NSE), and squamous cell carcinoma antigen (SCC) for stage I non-small-cell lung cancer NSCLC are limited.

High levels of neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125) and squamous cell carcinoma antigen (SCC) were detected in 306 (63.6%), 89 (18.5%) and 125 (26.0%) non-small cell lung cancer patients, respectively.

High serum neuron-specific enolase is associated with lung cancer and peripheral nerve tumors.

High serum neuron specific enolase expression is associated with lung cancer.

High serum NSE levels are associated with small-cell lung cancer.

The present study indicated that serum neuron-specific enolase is of no prognostic significance in patients with non-small cell lung cancer

CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer

this study shows that neuron-specific enolase level is both a predictive marker of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors treatment and a prognostic marker in non-small cell lung cancer harboring EGFR mutations patients

High neuron-specific enolase expression is associated with poor response to chemotherapy in small cell lung cancer.

Significant levels of CEA, CYFRA 21-1, NSE, and TSGF were detected in the serum. The amounts found were useful for diagnosing non-small cell lung cancer (NSCLC) patients who depended on the currently limited biomarker development.

BALF and serum NSE, CEA, and CYFRA21.1 elevated in lung cancer, which had prompt value for pathology, especially significant for BALF.

elevated preoperative NSE serum level is adverse predictive and prognostic indicator in adenosquamous lung carcinoma

High Neuron-Specific Enolase expression is associated with poor response to therapy in small cell lung cancer.

we conducted a retrospective study to evaluate the correlation between clinical-pathological parameters, serum levels of neuron-specific enolase and CYFRA21-1, and bone metastases in lung cancer patients.Multivariate logistic regression analysis showed that patients' age concentrations of neuron-specific enolase and histopathological types were the independent risk factors for bone metastases in patients with lung cancer

serum level elevated in small cell lung cancer patients with shorter progression-free survival

The detection of TK1 combined with that of cytokeratin-19 fragment (CYFRA21-1), CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and small cell lung cancer, respectively.

ProGRP and NSE serum expression levels predict therapeutic drug response in Chinese lung cancer patients.

The reduction in serum level of CYFRA21-1 or CEA might be a reliable biomarker to predict immunotherapy efficacy in non-small cell lung cancer patients. NSE was not significant for monitoring the efficacy of nivolumab.

Studied association of progastrin-releasing peptide (proGRP), neuron specific enolase (NSE), chromogranin a (CgA), and squamous cell cancer antigen (SCCA1) in pulmonary neuroendocrine tumor (PNET) and non-small-cell lung carcinoma (NSCLC). Results showed ProGRP can distinguish PNET patients from NSCLC patients, and with adjusted NSE values, it can differentiate the PNET group from the benign disease group.

Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis.